Science and Research
The Microcyn®Technology is unique in many ways.
Developed and produced by Sonoma Pharmaceuticals (Nasdaq: SNOA), formerly Oculus Innovative Sciences Inc. (Nasdaq:OCLS), a U.S. listed biopharmaceutical company(GMP) under continuous refinement for over 16 years
The original and very first hypochlorous acid (HOCl) introduced into the U.S. advanced wound care market
World’s best selling hypochlorous (HOCl) wound treatment product healing over 5 million people, without any significant adverse events.
Used daily in over 20 countries and over 400 hospitals in the U.S.
Its unique solution chemistry is proven safe and effective in helping to reduce itch, scarring, inflammation, skin infection and improved healing in over 40+ clinical trials
Patented by 53 issued patents and 109 pending patents worldwide
Has obtained 16 FDA (U.S. Food and Drug Administration) and 20 CE (Conformité Européenne) approvals
Registered under MDCO (Medical Device Control Office) in the Department of Health of Hong Kong for Microdacyn60